CAR T-cell therapy wins expert panel approval for leukemia treatment: What does this mean for myeloma patients?
Week in Review
Are Cure Claims for CAR T-Cell Therapy Premature?
Week in Review
Is prevention of myeloma within reach?
Week in Review
Myeloma News Roundup: ASCO Abstracts Released, China Meetings Succeed, and iStopMM Clinic Officially Opens
Week in Review
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study
This study sheds light on the expected outcome of relapsed myeloma patients that are refractory to a PI and an IMiD.